To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

Alexion Pharmaceuticals

Status: Completed

Conditions: ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Study type: Observational

Funder types: Industry

Identifiers

NCT01755429

C11-004J

Details and patient eligibility

About

This protocol is intended to formally collect data on the treatment of aHUS with eculizumab in Japanese patients.

Enrollment: 2 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patient and/or legal guardian must be willing and able to give written informed consent and id the patient is not an adult and able to read and write, the patient is willing to give written informed assent
2. Eculizumab treatment initiated as personal importation for aHUS in 201

Exclusion criteria

Not Applicable